Relmacabtagene Autoleucel in Hematologic Malignancies
To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world
Lymphoma, B-Cell|Large B-cell Lymphoma|Follicular Lymphoma
BIOLOGICAL: Relmacabtagene Autoleucel
ORR, Percentage of participants with CR \[CMR;CRR\] or PR \[partial metabolic response (PMR);, 15 years
CRR, Complete response rate, 15 years|Duration of response (DOR), Time from first response(PR or CR) to disease progression or death from any cause., 15 years|Progression-Free Survival (PFS), PFS is defined as the time from the Relmacabtagene Autoleucel infusion date to the date of disease progression per Lugano classification or death from any cause., 15 years|Overall Survival (OS), OS is defined as the time from Relmacabtagene Autoleucel infusion to the date of death from any cause., 15 years|Adverse events (AEs), Types, frequency, and severity of adverse events and laboratory anomalies Physiological parameter, 15 years
The purpose of this study is to observationally evaluate the efficacy and safety data of Relmacabtagene Autoleucel for the treatment of patients with hematologic malignancies for up to 15 years after infusion. The treating physician will determine the most appropriate diagnostic and therapeutic regimen for the patient based on clinical practice. No therapeutic intervention will be administered to patients in this study.